missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ Human Relaxin-2 Recombinant Protein, PeproTech®
Click to view available options
Quantity:
1 mg
100 μg
25 μg
250 μg
5 μg
500 μg
Unit Size:
100µg
1mg
250µg
25µg
500µg
5µg
Description
Recombinant Human Relaxin-2 is a non-glycosylated, 6.0 kDa, disulfide-linked, heterodimeric protein consisting of a 24 amino acid A-chain, and a 29 amino acid B-chain. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Relaxin 1 (also referred to as Relaxin or RLXH1) is a peptide hormone produced by the corpora lutea of the ovary during pregnancy in many mammalian species, including human. The secretion of the hormone into the blood stream just before parturition results in a marked softening and lengthening of the pubic symphysis and a softening of the cervix, which facilitates the birth process. By inhibiting uterine contractions, Relaxin 1 may influence the timing of parturition. Like insulin, Relaxin 1 consists of two peptide chains, A and B, covalently linked by disulfide bonds. By further analogy to insulin, the two peptides are synthesized as a single-chain precursor polypeptide with the B chain at the amino-terminus. The gene that encodes the human Relaxin 1 protein maps to chromosome 9. Relaxin 2, a related protein, is selectively expressed in the ovary during pregnancy. The gene that encodes the human Relaxin 2 protein also maps to chromosome 9.
Specifications
Specifications
| Accession Number | P04090 |
| For Use With (Application) | Functional Assay |
| Formulation | protein with no preservative |
| Gene ID (Entrez) | 6019 |
| Molecular Weight (g/mol) | 6 kDa |
| Name | Human Relaxin-2 |
| Quantity | 5 μg |
| Source | E. coli |
| Regulatory Status | RUO |
| Endotoxin Concentration | <1 EU/ μg |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction